LYEL Earnings Lyell Immunopharma, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–30 of 30
| Q3 2026 | 2026-09-30 | -1.86 | 2026-11-04 | 10-Q |
| Q2 2026 | 2026-06-30 | -1.92 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -1.10 | 2026-05-06 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -7.50 | 2026-03-12 | 10-K |
| FY 2025 | 2025-12-31 | -16.06 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -2.13 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -2.89 | 2025-08-12 | 10-Q |
| Q1 2025 | 2025-03-31 | -3.54 | 2025-05-13 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -14.36 | 2025-03-11 | 10-K |
| FY 2024 | 2024-12-31 | -26.23 | 2025-03-11 | 10-K |
| Q3 2024 | 2024-09-30 | -3.48 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -3.59 | 2024-08-07 | 10-Q |
| Q1 2024 | 2024-03-31 | -4.80 | 2024-05-06 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -4.10 | 2024-02-28 | 10-K |
| FY 2023 | 2023-12-31 | -18.70 | 2024-02-28 | 10-K |
| Q3 2023 | 2023-09-30 | -4.00 | 2023-11-07 | 10-Q |
| Q2 2023 | 2023-06-30 | -5.20 | 2023-08-08 | 10-Q |
| Q1 2023 | 2023-03-31 | -5.40 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -0.60 | 2023-02-28 | 10-K |
| FY 2022 | 2022-12-31 | -14.80 | 2023-02-28 | 10-K |
| Q3 2022 | 2022-09-30 | -5.60 | 2022-11-08 | 10-Q |
| Q2 2022 | 2022-06-30 | -3.00 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -5.60 | 2022-05-10 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | 60.40 | 2022-03-29 | 10-K |
| FY 2021 | 2021-12-31 | -36.80 | 2022-03-29 | 10-K |
| Q3 2021 | 2021-09-30 | -4.00 | — | — |
| Q2 2021 | 2021-06-30 | -29.40 | — | — |
| Q1 2021 | 2021-03-31 | -63.80 | — | — |
| FY 2020 | 2020-12-31 | -313.80 | — | — |
| FY 2019 | 2019-12-31 | -480.80 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.